Trial in Australia, Europe will test heart drug in ALS patients

Trial in Australia, Europe will test heart drug in ALS patients

A clinical trial in Australia and Europe will test whether trimetazidine, a medication commonly used to treat heart conditions, could help improve function and quality of life for amyotrophic lateral sclerosis (ALS) patients. The trial, led by University of Queensland researcher Shyuan Ngo, PhD, and her team at the…

Guest Voice: My ALS speech issues have resulted in unexpected gifts

Until recently, my language skills and speech were best buddies. They were happily and symbiotically entwined, each supporting the other with comfort and ease. Language — the software system — was the one with all the good ideas, reacting to the environment in milliseconds like a gleeful toddler and formulating…

Promising BCI tech can translate thoughts to speech for ALS patients

New research is bringing mind-to-speech technology a step closer to reality for people with paralysis, including those with amyotrophic lateral sclerosis (ALS) who lose the ability to speak. A proof-of-principle study shows that a brain-computer interface (BCI) can translate a person’s silent thoughts into spoken words and could provide…

Building a home amid the loss and uncertainty of ALS

Last Sunday, on the morning of our 22nd wedding anniversary, as I was getting my husband, Todd, out of bed, he asked if I’d heard the song “To Build a Home.” I hadn’t. “Alexa, play ‘To Build a Home‘ by the Cinematic Orchestra and Patrick Watson,” Todd said.

New analysis shows Radicava ORS slows ALS decline

A retrospective analysis using data from two clinical studies and their extension periods showed that Radicava ORS, an oral formulation of edaravone, slows functional decline and helps adults with amyotrophic lateral sclerosis (ALS) live longer. “This analysis provides additional data to help characterize functional outcomes and potential impact of…